8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
DexCom reports 13% revenue growth and raises 2026 margin guidance
Filed with the SEC on · Summarized by InvestorsBot
DexCom’s second-quarter 2026 revenue rose 13% year over year to $1.308 billion, while GAAP net income increased to $249.1 million, or $0.64 per diluted share, from $179.8 million, or $0.45, a year earlier. The company raised its 2026 guidance to $5.18 billion-$5.25 billion in revenue, approximately 64% non-GAAP gross margin, 23.5%-24% non-GAAP operating margin, and 31.5%-32% adjusted EBITDA margin; as of June 30, DexCom had $1.95 billion in cash, cash equivalents and marketable securities.